Saram ConsultingGxP & AI Consulting for Life Sciences. Custom AI integrations, Part 11 compliance validation, and equity-based engineering partnerships for biotech.Explore Services at saram.io →
← Back to Home

Insmed Incorporated

NASDAQ: INSM ↗$126.29 USD~$13B MCAP
#Rare Diseases#Pulmonary#Pulmonology

Commercial-stage biopharmaceutical company developing therapies for rare and serious diseases, including ARIKAYCE for refractory NTM lung infection and brensocatib for bronchiectasis.

Company Info

Sector:Biotechnology
Headquarters:Bridgewater, New Jersey, USA
Founded:1999
Website:insmed.com/

Upcoming Milestones & Key Dates

Late 2026
PDUFA

Brensocatib FDA decision (bronchiectasis)

2027 H1
Clinical Readout

TPIP Phase 3 long-term data

Clinical Development Pipeline

ARIKAYCE (amikacin liposome inhalation suspension)

Target: Amikacin
Refractory NTM lung infection
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Brensocatib

Target: DPP1
Bronchiectasis
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Treprostinil palmitil (TPIP)

Target: Prostacyclin
Pulmonary arterial hypertension (PAH)
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Recent News

Leadership Team

Will Lewis

Chair and Chief Executive Officer

Sara Bonstein

Chief Financial Officer

Chief Medical Officer

Head of Clinical Development

Careers & Job Openings

Associate Director, Regulatory Affairs Project Manager

Regulatory Affairs
Bridgewater, NJ
Apply Now →

Therapeutic Specialist, Salt Lake City

Sales
Working from Home
Apply Now →

Manager, DSPV Pharmacovigilance Agreements

Pharmacovigilance
Working from Home
Apply Now →